BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miyahara K, Nouso K, Yamamoto K. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol 2014; 20(15): 4151-4159 [PMID: 24764653 DOI: 10.3748/wjg.v20.i15.4151] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Chen H, Yang X, Yu Z, Cheng Z, Yuan H, Zhao Z, Wu G, Xie N, Yuan X, Sun Q, Zhang W. Synthesis and biological evaluation of α-santonin derivatives as anti-hepatoma agents. Eur J Med Chem 2018;149:90-7. [PMID: 29499490 DOI: 10.1016/j.ejmech.2018.02.073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7(8): 1041-1053 [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
3 Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, Yu H, Lin H, Cai X. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Letters 2015;367:1-11. [DOI: 10.1016/j.canlet.2015.06.019] [Cited by in Crossref: 111] [Cited by in F6Publishing: 121] [Article Influence: 15.9] [Reference Citation Analysis]
4 Jiang H, Wu D, Xu D, Yu H, Zhao Z, Ma D, Jin J. Eupafolin Exhibits Potent Anti-Angiogenic and Antitumor Activity in Hepatocellular Carcinoma. Int J Biol Sci 2017;13:701-11. [PMID: 28655996 DOI: 10.7150/ijbs.17534] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
5 Dong X, Liu F, Li M. Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells. Anticancer Drugs 2016;27:286-99. [PMID: 26704389 DOI: 10.1097/CAD.0000000000000329] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
6 Siddiqui S, Ahmad R, Khan MA, Upadhyay S, Husain I, Srivastava AN. Cytostatic and Anti-tumor Potential of Ajwa Date Pulp against Human Hepatocellular Carcinoma HepG2 Cells. Sci Rep 2019;9:245. [PMID: 30664656 DOI: 10.1038/s41598-018-36475-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
7 Yuan X, Chen H, Li X, Dai M, Zeng H, Shan L, Sun Q, Zhang W. Inhibition of protein kinase C by isojacareubin suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo. Sci Rep 2015;5:12889. [PMID: 26245668 DOI: 10.1038/srep12889] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
8 Chen QW, Teng WJ, Chen Q. Chest wall hernia induced by high intensity focused ultrasound treatment of unresectable massive hepatocellular carcinoma: A case report. Oncol Lett 2016;12:627-30. [PMID: 27347191 DOI: 10.3892/ol.2016.4618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36 [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 76] [Article Influence: 13.7] [Reference Citation Analysis]
10 Heindryckx F, Gerwins P. Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol 2015; 7(2): 165-176 [PMID: 25729472 DOI: 10.4254/wjh.v7.i2.165] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
11 Kalyan A, Nimeiri H, Kulik L. Systemic therapy of hepatocellular carcinoma: current and promising. Clin Liver Dis 2015;19:421-32. [PMID: 25921671 DOI: 10.1016/j.cld.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
12 Kawabata M, Umemoto N, Shimada Y, Nishimura Y, Zhang B, Kuroyanagi J, Miyabe M, Tanaka T. Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. Toxicol Sci 2015;143:374-84. [PMID: 25370841 DOI: 10.1093/toxsci/kfu235] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
13 Omar HA, Zaher DM, Srinivasulu V, Hersi F, Tarazi H, Al-Tel TH. Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma. Eur J Med Chem 2017;139:804-14. [PMID: 28865276 DOI: 10.1016/j.ejmech.2017.08.054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Okusaka T, Otsuka T, Ueno H, Mitsunaga S, Sugimoto R, Muro K, Saito I, Tadayasu Y, Inoue K, Loembé AB, Ikeda M. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Sci 2016;107:1791-9. [PMID: 27627050 DOI: 10.1111/cas.13077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
15 Pratama MY, Pascut D, Massi MN, Tiribelli C. The role of microRNA in the resistance to treatment of hepatocellular carcinoma. Ann Transl Med 2019;7:577. [PMID: 31807558 DOI: 10.21037/atm.2019.09.142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
16 Mehdizadeh A, Somi MH, Darabi M, Farajnia S, Akbarzadeh A, Montazersaheb S, Yousefi M, Bonyadi M. Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2. Artif Cells Nanomed Biotechnol 2017;45:1612-9. [PMID: 28058860 DOI: 10.1080/21691401.2016.1269117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
17 Shen S, Sun CY, Du XJ, Li HJ, Liu Y, Xia JX, Zhu YH, Wang J. Co-delivery of platinum drug and siNotch1 with micelleplex for enhanced hepatocellular carcinoma therapy. Biomaterials. 2015;70:71-83. [PMID: 26302232 DOI: 10.1016/j.biomaterials.2015.08.026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
18 Hong TH, Jeena MT, Kim OH, Kim KH, Choi HJ, Lee KH, Hong HE, Ryu JH, Kim SJ. Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells. Sci Rep 2021;11:874. [PMID: 33441650 DOI: 10.1038/s41598-020-79536-z] [Reference Citation Analysis]
19 Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 Yang Q, Zhou C, Zhao Q, Chu Z, Yang D, Jia N. Sonochemical assisted synthesis of dual functional BSA nanoparticle for the removal of excessive bilirubin and strong anti-tumor effects. Materials Science and Engineering: C 2019;100:688-96. [DOI: 10.1016/j.msec.2019.03.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]